5 Pharmaceutical Stocks to Buy Now

by Portfolio Grader | December 13, 2013 7:45 am

This week, five pharmaceutical stocks are improving their overall ratings on Portfolio Grader[1]. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Ocera Therapeutics, Inc. (OCRX[2]) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. For more information, get Portfolio Grader’s complete analysis of OCRX stock[3].

Johnson & Johnson (JNJ[4]) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. At present, the stock has a dividend yield of 2.6%. For more information, get Portfolio Grader’s complete analysis of JNJ stock[5].

The rating of Bristol-Myers Squibb Company (BMY[6]) moves up this week, rising from a C to a B. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock[7].

Watson Pharmaceuticals (WPI[8]) gets a higher grade this week, advancing from a B last week to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock[9].

This is a strong week for Repros Therapeutics (RPRX[10]). The company’s rating climbs to A from the previous week’s B. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. Shares of RPRX have increased 11.7% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of RPRX stock[11].

Louis Navellier’s proprietary Portfolio Grader[12] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[13].

Endnotes:

  1. Portfolio Grader: https://navelliergrowth.investorplace.com/portfolio-grader/
  2. OCRX: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=OCRX
  3. For more information, get Portfolio Grader’s complete analysis of OCRX stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=OCRX
  4. JNJ: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=JNJ
  5. For more information, get Portfolio Grader’s complete analysis of JNJ stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=JNJ
  6. BMY: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=BMY
  7. For more information, get Portfolio Grader’s complete analysis of BMY stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=BMY
  8. WPI: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=WPI
  9. For more information, get Portfolio Grader’s complete analysis of WPI stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=WPI
  10. RPRX: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=RPRX
  11. For more information, get Portfolio Grader’s complete analysis of RPRX stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=RPRX
  12. Portfolio Grader: https://navelliergrowth.investorplace.com/portfolio-grader/
  13. here: https://navelliergrowth.investorplace.com/portfolio-grader/

Source URL: https://investorplace.com/2013/12/5-pharmaceutical-stocks-to-buy-now-ocrx-jnj-bmy/

Copyright ©2024 InvestorPlace unless otherwise noted.